JP2018535226A - ビス−ピリダジン化合物およびがんの治療におけるその使用 - Google Patents

ビス−ピリダジン化合物およびがんの治療におけるその使用 Download PDF

Info

Publication number
JP2018535226A
JP2018535226A JP2018526706A JP2018526706A JP2018535226A JP 2018535226 A JP2018535226 A JP 2018535226A JP 2018526706 A JP2018526706 A JP 2018526706A JP 2018526706 A JP2018526706 A JP 2018526706A JP 2018535226 A JP2018535226 A JP 2018535226A
Authority
JP
Japan
Prior art keywords
formula
pharmaceutically acceptable
pyridazin
compound
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018526706A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535226A5 (enExample
Inventor
モーリス・レイモンド・バーショイル・フィンレイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
AstraZeneca AB
Original Assignee
Cancer Research Technology Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd, AstraZeneca AB filed Critical Cancer Research Technology Ltd
Publication of JP2018535226A publication Critical patent/JP2018535226A/ja
Publication of JP2018535226A5 publication Critical patent/JP2018535226A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2018526706A 2015-11-27 2016-11-25 ビス−ピリダジン化合物およびがんの治療におけるその使用 Withdrawn JP2018535226A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1520959.6A GB201520959D0 (en) 2015-11-27 2015-11-27 Bis-pyridazine compounds and their use in treating cancer
GB1520959.6 2015-11-27
PCT/EP2016/078899 WO2017089587A1 (en) 2015-11-27 2016-11-25 Bis-pyridazine compounds and their use in treating cancer

Publications (2)

Publication Number Publication Date
JP2018535226A true JP2018535226A (ja) 2018-11-29
JP2018535226A5 JP2018535226A5 (enExample) 2019-11-28

Family

ID=55177338

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018526706A Withdrawn JP2018535226A (ja) 2015-11-27 2016-11-25 ビス−ピリダジン化合物およびがんの治療におけるその使用

Country Status (17)

Country Link
US (2) US10196382B2 (enExample)
EP (1) EP3380468B8 (enExample)
JP (1) JP2018535226A (enExample)
KR (1) KR20180083426A (enExample)
CN (1) CN108349951B (enExample)
AR (1) AR106849A1 (enExample)
AU (1) AU2016360970B2 (enExample)
CA (1) CA3005102A1 (enExample)
DK (1) DK3380468T3 (enExample)
ES (1) ES2806723T3 (enExample)
GB (1) GB201520959D0 (enExample)
IL (1) IL259358A (enExample)
MX (1) MX2018006374A (enExample)
RU (1) RU2018122012A (enExample)
SG (1) SG11201803814SA (enExample)
TW (1) TW201731837A (enExample)
WO (1) WO2017089587A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11331417B2 (en) 2015-09-29 2022-05-17 Shanghai Clinical Engine Technology Development Co., Ltd. Magnetic target separation instrument and application thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
KR20250137464A (ko) 2024-03-11 2025-09-18 이석재 숏블라스트머신의 연마재탱크

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108785305B (zh) 2011-11-21 2021-10-29 卡利泰拉生物科技公司 谷氨酰胺酶的杂环抑制剂
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
KR20160100407A (ko) * 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11331417B2 (en) 2015-09-29 2022-05-17 Shanghai Clinical Engine Technology Development Co., Ltd. Magnetic target separation instrument and application thereof

Also Published As

Publication number Publication date
CN108349951B (zh) 2020-11-13
CN108349951A (zh) 2018-07-31
AR106849A1 (es) 2018-02-21
US10577354B2 (en) 2020-03-03
AU2016360970B2 (en) 2019-11-07
GB201520959D0 (en) 2016-01-13
IL259358A (en) 2018-07-31
US20190169172A1 (en) 2019-06-06
US10196382B2 (en) 2019-02-05
TW201731837A (zh) 2017-09-16
US20170152244A1 (en) 2017-06-01
WO2017089587A1 (en) 2017-06-01
MX2018006374A (es) 2019-07-08
KR20180083426A (ko) 2018-07-20
CA3005102A1 (en) 2017-06-01
EP3380468B8 (en) 2020-11-04
EP3380468B1 (en) 2020-05-20
RU2018122012A (ru) 2019-12-30
EP3380468A1 (en) 2018-10-03
AU2016360970A1 (en) 2018-07-05
ES2806723T3 (es) 2021-02-18
SG11201803814SA (en) 2018-06-28
DK3380468T3 (da) 2020-07-27

Similar Documents

Publication Publication Date Title
US10294221B2 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
JP6821680B2 (ja) 1,3,4−チアジアゾール化合物およびがんの治療におけるその使用
JP6999550B2 (ja) 1,3,4-チアジアゾール化合物およびがんの治療におけるその使用
US10577354B2 (en) Bis-pyridazine compounds and their use in treating cancer
ES2759940T3 (es) Compuestos de 1,3,4-tiadiazol y su uso para tratar el cáncer
HK1260707B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260707A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260702B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260702A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191017

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20191127